MX2020012281A - Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. - Google Patents

Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.

Info

Publication number
MX2020012281A
MX2020012281A MX2020012281A MX2020012281A MX2020012281A MX 2020012281 A MX2020012281 A MX 2020012281A MX 2020012281 A MX2020012281 A MX 2020012281A MX 2020012281 A MX2020012281 A MX 2020012281A MX 2020012281 A MX2020012281 A MX 2020012281A
Authority
MX
Mexico
Prior art keywords
bisfluoroalkyl
compositions
methods
benzodiazepinone compounds
compounds
Prior art date
Application number
MX2020012281A
Other languages
English (en)
Inventor
Bruce S Fischer
Gaurav Bajaj
David Sidransky
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2020012281A publication Critical patent/MX2020012281A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos de uso para composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona, que incluyen compuestos de la fórmula (I) o profármacos de los mismos; (ver Fórmula) para tratar enfermedades o trastornos como el cáncer.
MX2020012281A 2018-05-15 2019-05-15 Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. MX2020012281A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671748P 2018-05-15 2018-05-15
PCT/US2019/032326 WO2019222298A1 (en) 2018-05-15 2019-05-15 Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2020012281A true MX2020012281A (es) 2021-01-29

Family

ID=68540867

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012281A MX2020012281A (es) 2018-05-15 2019-05-15 Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.

Country Status (11)

Country Link
US (1) US20210220372A1 (es)
EP (1) EP3793563A4 (es)
JP (1) JP2021523189A (es)
KR (1) KR20210008527A (es)
CN (1) CN112236147A (es)
AU (1) AU2019271151A1 (es)
BR (1) BR112020023204A2 (es)
CA (1) CA3100202A1 (es)
MX (1) MX2020012281A (es)
SG (1) SG11202011227VA (es)
WO (1) WO2019222298A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210379079A1 (en) * 2018-05-06 2021-12-09 Ayala Pharmaceuticals Inc. Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
CN112203661A (zh) * 2018-05-24 2021-01-08 艾雅拉制药公司 包含双氟烷基-1,4-苯并二氮杂*酮化合物与免疫治疗剂的组合物和其使用方法
JP2022533100A (ja) * 2019-05-15 2022-07-21 アヤラ ファーマシューティカルズ インコーポレイテッド Ｎｏｔｃｈ活性化乳がんを治療するためのビスフルオロアルキル－１，４－ベンゾジアゼピノン化合物
US20230047191A1 (en) * 2021-08-05 2023-02-16 Celanese Eva Performance Polymers Llc Implantable Medical Device for the Delivery of Bisphosphonate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0025173D0 (en) * 2000-10-13 2000-11-29 Merck Sharp & Dohme Therapeutic agents
WO2005040126A1 (en) * 2003-10-06 2005-05-06 F. Hoffman-La Roche Ag Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors
WO2007100895A2 (en) * 2006-02-27 2007-09-07 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
TWI530489B (zh) * 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
TWI614238B (zh) * 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
WO2014165718A1 (en) * 2013-04-04 2014-10-09 Bristol-Myers Squibb Company Combination therapy for the treatment of proliferative diseases
CN106943596A (zh) * 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合

Also Published As

Publication number Publication date
AU2019271151A2 (en) 2021-01-14
AU2019271151A1 (en) 2021-01-07
EP3793563A4 (en) 2022-02-23
US20210220372A1 (en) 2021-07-22
JP2021523189A (ja) 2021-09-02
BR112020023204A2 (pt) 2021-02-23
CA3100202A1 (en) 2019-11-21
WO2019222298A1 (en) 2019-11-21
KR20210008527A (ko) 2021-01-22
SG11202011227VA (en) 2020-12-30
EP3793563A1 (en) 2021-03-24
CN112236147A (zh) 2021-01-15

Similar Documents

Publication Publication Date Title
PH12021500014A1 (en) Fused ring compounds
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
PH12021551065A1 (en) Fused ring compounds
PH12018501268A1 (en) Compounds useful as kinase inhibitors
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
EP4233910A3 (en) Methods of treatment of cholestatic diseases
MX2020011234A (es) Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3).
PH12017502123A1 (en) Substituted benzamides and methods of use thereof
MX2019005934A (es) Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac).
PH12019500196A1 (en) Compounds and compositions and uses thereof
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
NZ761519A (en) Nlrp3 modulators
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
ZA202006071B (en) Antiproliferation compounds and uses thereof
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.